State AGs lobby FDA to reconsider nod for powerful Zogenix painkiller

Tracy Staton The FDA approved a powerful new painkiller from Zogenix despite opposition from its own advisory panel. Now, attorneys general from 28 states have jumped in to ask the ...

For Engagement, DIG Looks toward Future

mia.burns By Mia Burns (mia.burns@ubm.com) During the past decade, a tidal wave of innovation specific to the market of devices to access digital content, services, and to conduct ...

FDA panel smiles on Bristol-Myers, AstraZeneca’s diabetes drug in do-over

Damian Garde Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, ...

Bristol-Myers licenses second-line HIV drug for cheap copies in poor nations

Tracy Staton Bristol-Myers Squibb agreed to license its HIV fighter Reyataz (atazanavir) to the Medicines Patent Pool, which will allow generics makers to turn out cheaper copies for ...

CTI, GKV Reach Agreement on Pixuvri Pricing

barbara.lempert Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI® (pixantrone) in Germany – Decision Applies to Patients with Aggressive B-cell Non-Hodgkin ...

Zafgen lands $45M round for obesity drug study

John Carroll FierceBiotech News

Provenge critic lied about her bets Dendreon stock would fall

Carly Helfand Analysts haven't exactly been high on Dendreon lately. The company's lead treatment, prostate cancer vaccine Provenge, continues to post sales losses, ...

More Pharma Jobs Are Disappearing: Forest And Eisai Cut Back

esilverman Yet another round of cutbacks in the pharmaceutical industry is unfolding. The latest to shrink operations is Forest Laboratories, which is slashing expenses by ...

Idenix fires off a shot in patent battle over Gilead’s sofosbuvir

Damian Garde As Gilead nears a virtually guaranteed FDA approval for the hepatitis C-fighting sofosbuvir, the biotech is facing intellectual property challenges from a bevy of competitors, ...

Eisai to cut R&D, even as it boosts its sales operation

Eric Palmer Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS